AM-1241– synthetic, CB 2 agonist


Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: Pain inhibition by receptors not present in the CNS                        (full – 2003)


Inhibition of Inflammatory Hyperalgesia by Activation of Peripheral CB2 Cannabinoid Receptors                          (full – 2003)



New Compound That Acts On Peripheral Receptors May Be Promising Treatment For Some Nerve Pain                            (news – 2003)


CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids                     (full – 2005)


Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain.                                      (abst – 2005) 


In vitro pharmacological characterization of AM1241: a protean agonist at the cannabinoid CB2 receptor?                                      (full – 2006)


AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis.                                      (abst – 2006)


The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset                                  (full – 2007)


Peripheral Cannabinoids Attenuate Carcinoma Induced Nociception in Mice (full – 2008)                     


Selective Activation of Cannabinoid CB2 Receptors Suppresses Neuropathic Nociception Induced by Treatment with the Chemotherapeutic Agent Paclitaxel in Rats (full – 2008)


The endocannabinoid system in amyotrophic lateral sclerosis.      (abst – 2008)


Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. (full – 2009)                     


Spinal and peripheral analgesic effects of the CB cannabinoid receptor agonist AM1241 in two models of bone cancer-induced pain.                                    (full – 2010)


A cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone loss. (abst – 2010)                    


Cannabinoids attenuate cancer pain and proliferation in a mouse model.

(full – 2011)


Self-medication of a cannabinoid CB(2) agonist in an animal model of neuropathic pain. (abst – 2011)




Regulation of hematopoietic stem cell trafficking and mobilization by the endocannabinoid system.  (abst – 2011)                           


Cannabinoid receptor 2 and its agonists mediate hematopoiesis and hematopoietic stem and progenitor cell mobilization. (abst – 2011)


Antinociceptive effects induced through the stimulation of spinal cannabinoid type 2 receptors in chronically inflamed mice                             (abst – 2011)   d_through_the_stimulation_of_spinal_cannabinoid_type_2_receptors_in_chronically_inflamed_mice_


Effects of a Selective Cannabinoid CB2 Agonist and Antagonist on Intravenous Nicotine Self Administration and Reinstatement of Nicotine Seeking.             (full – 2012)


Therapeutic modulation of cannabinoid lipid signaling: Metabolic profiling of a novel antinociceptive cannabinoid-2 receptor agonist.                                 (abst – 2012)


Prevention of Fibrosis Progression in CCl4-Treated Rats: Role of the Hepatic Endocannabinoid and Apelin Systems                                            (abst – 2012)


Diuretic effects of cannabinoids.  (abst – 2012)


Cannabinoid Receptors as Therapeutic Targets for Dialysis-Induced Peritoneal Fibrosis. (abst – 2013)





Share a link for